Hypercholesterolemia - Pipeline Review, H2 2013

Date: September 20, 2013
Pages: 120
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H807BC988B3EN
Leaflet:

Download PDF Leaflet

Hypercholesterolemia - Pipeline Review, H2 2013
Hypercholesterolemia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Hypercholesterolemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. Hypercholesterolemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Hypercholesterolemia.
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypercholesterolemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercholesterolemia
Hypercholesterolemia Therapeutics under Development by Companies
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hypercholesterolemia Therapeutics - Products under Development by Companies
Hypercholesterolemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypercholesterolemia Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Eli Lilly and Company
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Pfizer Inc.
Santaris Pharma A/S
Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc.
Spherix Incorporated
Ache Laboratorios Farmaceuticos S/A
Catabasis Pharmaceuticals, Inc.
PepTcell Limited
Relypsa, Inc.
Esperion Therapeutics, Inc.
Serometrix, LLC
FORMAC Pharmaceuticals N.V.
Madeira Therapeutics
Hypercholesterolemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SPC-4955 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGL-3196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-ApoB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETC-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ezetimibe + atorvastatin calcium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alfadex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-770767 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-04950615 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLY-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(SPX-106 + D-tagatose) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-962476 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
1D05-FAB - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
(ezetimibe + rosuvastatin calcium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-3015014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HeartVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-05335810 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-852927 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PCSK-9 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGF-A Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SX-PCK9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAT-2003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-806 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aplexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DYB-186 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pravastatin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-1028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Compound-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LUM-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercholesterolemia Therapeutics - Drug Profile Updates
Hypercholesterolemia Therapeutics - Discontinued Products
Hypercholesterolemia Therapeutics - Dormant Products
Hypercholesterolemia - Product Development Milestones
Featured News & Press Releases
Sep 03, 2013: Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia
Aug 31, 2013: Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
Aug 30, 2013: Esperion Therapeutics to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia
Aug 28, 2013: Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference
Aug 21, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Hypertriglyceridemia and Hypercholesterolemia
Jun 07, 2013: Esperion Therapeutics's ETC-1002 Meets Primary Endpoint In Phase II Study In Patients With Hypercholesterolemia
May 02, 2013: Esperion's ETC-1002 Meets Primary Endpoint In Phase II Study In Hypercholesterolemic Patients With Type 2 Diabetes
Mar 25, 2013: AstraZeneca Settles Litigation Over Crestor Patent
Mar 11, 2013: Alternative Cholesterol Lowering Drug Effective In Patients Who Can’t Tolerate Other Statins, Study Finds
Feb 04, 2013: US Consumers Approach Court To Consider Recall Of Ranbaxy's Generic Lipitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Hypercholesterolemia, H2 2013
Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2013
Bristol-Myers Squibb Company, H2 2013
Johnson & Johnson, H2 2013
Amgen Inc., H2 2013
Eli Lilly and Company, H2 2013
Tekmira Pharmaceuticals Corp., H2 2013
Merck & Co., Inc., H2 2013
Pfizer Inc., H2 2013
Santaris Pharma A/S, H2 2013
Alnylam Pharmaceuticals, Inc, H2 2013
Regeneron Pharmaceuticals, Inc., H2 2013
Spherix Incorporated, H2 2013
Ache Laboratorios Farmaceuticos S/A, H2 2013
Catabasis Pharmaceuticals, Inc., H2 2013
PepTcell Limited, H2 2013
Relypsa, Inc., H2 2013
Esperion Therapeutics, Inc., H2 2013
Serometrix, LLC, H2 2013
FORMAC Pharmaceuticals N.V., H2 2013
Madeira Therapeutics, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Hypercholesterolemia Therapeutics - Drug Profile Updates
Hypercholesterolemia Therapeutics - Discontinued Products
Hypercholesterolemia Therapeutics - Dormant Products
Hypercholesterolemia Therapeutics - Dormant Products (Contd..1)

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, H2 2013
Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

COMPANIES MENTIONED

Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Eli Lilly and Company
Tekmira Pharmaceuticals Corp.
Merck & Co., Inc.
Pfizer Inc.
Santaris Pharma A/S
Alnylam Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc.
Spherix Incorporated
Ache Laboratorios Farmaceuticos S/A
Catabasis Pharmaceuticals, Inc.
PepTcell Limited
Relypsa, Inc.
Esperion Therapeutics, Inc.
Serometrix, LLC
FORMAC Pharmaceuticals N.V.
Madeira Therapeutics

Ask Your Question

Hypercholesterolemia - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: